☰

Michael A. Schwarzschild - Publications

Affiliations: 
Neurology Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States 
Tree Info Grants Similar researchers PubMed Report error

182/280 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Olsen A, Locascio J, Tuncali I, Laroussi N, Abatzis E, Kamenskaya P, Kuras Y, Yi T, Videnovic A, Hayes M, Ho G, Paulson J, Khurana V, Herrington T, Hyman B, ... ... Schwarzschild M, et al. Health phenome of Parkinson's patients reveals prominent mood-sleep cluster. Research Square. PMID 38196602 DOI: 10.21203/rs.3.rs-3683455/v1  0.556
2023 Flores-Torres MH, Bjornevik K, Zhang X, Gao X, Hung AY, Schwarzschild MA, Chen X, Ascherio A. Hair color, family history of melanoma, and the risk of Parkinson's disease: An analysis update. Parkinsonism & Related Disorders. 119: 105965. PMID 38142631 DOI: 10.1016/j.parkreldis.2023.105965  0.364
2023 Srivastava P, Nishiyama S, Zhou F, Lin SH, Srivastava A, Su C, Xu Y, Peng W, Levy M, Schwarzschild M, Chen X. Peripheral MC1R Activation Modulates Immune Responses and is Neuroprotective in a Mouse Model of Parkinson's Disease. Journal of Neuroimmune Pharmacology : the Official Journal of the Society On Neuroimmune Pharmacology. PMID 38110615 DOI: 10.1007/s11481-023-10094-7  0.346
2023 Xia N, Madore V, Albalakhi A, Lin S, Stimpson T, Xu Y, Schwarzschild MA, Bakshi R. Microglia-dependent neuroprotective effects of 4-octyl itaconate against rotenone-and MPP+-induced neurotoxicity in Parkinson's disease. Scientific Reports. 13: 15539. PMID 37730914 DOI: 10.1038/s41598-023-42813-8  0.323
2023 Palacios N, Wilkinson J, Bjornevik K, Schwarzschild MA, McIver L, Ascherio A, Huttenhower C. Metagenomics of the Gut Microbiome in Parkinson's Disease: Prodromal Changes. Annals of Neurology. PMID 37314861 DOI: 10.1002/ana.26719  0.375
2023 Di Luca DG, Macklin EA, Hodgeman K, Lopez G, Pothier L, Callahan KF, Lowell J, Chan J, Videnovic A, Lungu C, Lang AE, Litvan I, Schwarzschild MA, Simuni T. Enrollment of Participants From Marginalized Racial and Ethnic Groups: A Comparative Assessment of the STEADY-PD III and SURE-PD3 Trials. Neurology. Clinical Practice. 13: e200113. PMID 36865634 DOI: 10.1212/CPJ.0000000000200113  0.316
2022 Crotty GF, Keavney JL, Alcalay RN, Marek K, Marshall GA, Rosas HD, Schwarzschild MA. Planning for Prevention of Parkinson Disease: Now Is the Time. Neurology. 99: 1-9. PMID 36219787 DOI: 10.1212/WNL.0000000000200789  0.351
2022 Patterson CG, Joslin E, Gil AB, Spigle W, Nemet T, Chahine L, Christiansen CL, Melanson E, Kohrt WM, Mancini M, Josbeno D, Balfany K, Griffith G, Dunlap MK, Lamotte G, ... ... Schwarzschild MA, et al. Study in Parkinson's disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial. Trials. 23: 855. PMID 36203214 DOI: 10.1186/s13063-022-06703-0  0.64
2022 Zhang X, Molsberry SA, Schwarzschild MA, Ascherio A, Gao X. Association of Diet and Physical Activity With All-Cause Mortality Among Adults With Parkinson Disease. Jama Network Open. 5: e2227738. PMID 35984656 DOI: 10.1001/jamanetworkopen.2022.27738  0.339
2022 Crotty GF, Schwarzschild MA. What to Test in Parkinson Disease Prevention Trials? Repurposed, Low-Risk, and Gene-Targeted Drugs. Neurology. 99: 34-41. PMID 35970592 DOI: 10.1212/WNL.0000000000200238  0.349
2022 Molsberry SA, Hughes KC, Schwarzschild MA, Ascherio A. Who to Enroll in Parkinson Disease Prevention Trials? The Case for Composite Prodromal Cohorts. Neurology. 99: 26-33. PMID 35970591 DOI: 10.1212/WNL.0000000000200788  0.336
2022 Berg D, Crotty GF, Keavney JL, Schwarzschild MA, Simuni T, Tanner C. Path to Parkinson Disease Prevention: Conclusion and Outlook. Neurology. 99: 76-83. PMID 35970586 DOI: 10.1212/WNL.0000000000200793  0.34
2022 Page A, Yung N, Auinger P, Venuto C, Glidden A, Macklin E, Omberg L, Schwarzschild MA, Dorsey ER. A Smartphone Application as an Exploratory Endpoint in a Phase 3 Parkinson's Disease Clinical Trial: A Pilot Study. Digital Biomarkers. 6: 1-8. PMID 35224425 DOI: 10.1159/000521232  0.314
2022 Sanchez AV, Ison JM, Hemley H, Willis A, Siddiqi B, Macklin EA, Ulysse C, Reynolds M, Schwarzschild MA, Jackson JD. Designing the fostering inclusivity in research engagement for underrepresented populations in Parkinson's disease study. Contemporary Clinical Trials. 106713. PMID 35202842 DOI: 10.1016/j.cct.2022.106713  0.314
2022 Cai W, Srivastava P, Feng D, Lin Y, Vanderburg CR, Xu Y, Mclean P, Frosch MP, Fisher DE, Schwarzschild MA, Chen X. Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson's disease. Molecular Neurodegeneration. 17: 16. PMID 35197079 DOI: 10.1186/s13024-022-00520-4  0.666
2022 Zhang X, Molsberry SA, Yeh TS, Cassidy A, Schwarzschild MA, Ascherio A, Gao X. Intake of Flavonoids and Flavonoid-Rich Foods, and Mortality Risk Among Individuals With Parkinson Disease: A Prospective Cohort Study. Neurology. PMID 35082171 DOI: 10.1212/WNL.0000000000013275  0.337
2022 Macklin EA, Ascherio A, Schwarzschild MA. Effect of Urate-Elevating Inosine on Progression of Early Parkinson Disease-Reply. Jama. 327: 85-86. PMID 34982121 DOI: 10.1001/jama.2021.21011  0.307
2021 Lungu C, Cedarbaum JM, Dawson TM, Dorsey ER, Faraco C, Federoff HJ, Fiske B, Fox R, Goldfine AM, Kieburtz K, Macklin EA, Matthews H, Rafaloff G, Saunders-Pullman R, Schor NF, ... Schwarzschild MA, et al. Seeking progress in disease modification in Parkinson disease. Parkinsonism & Related Disorders. PMID 34561166 DOI: 10.1016/j.parkreldis.2021.09.006  0.359
2021 Schwarzschild MA, Ascherio A, Casaceli C, Curhan GC, Fitzgerald R, Kamp C, Lungu C, Macklin EA, Marek K, Mozaffarian D, Oakes D, Rudolph A, Shoulson I, Videnovic A, et al. Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial. Jama. 326: 926-939. PMID 34519802 DOI: 10.1001/jama.2021.10207  0.377
2021 Liu G, Peng J, Liao Z, Locascio JJ, Corvol JC, Zhu F, Dong X, Maple-Grødem J, Campbell MC, Elbaz A, Lesage S, Brice A, Mangone G, Growdon JH, Hung AY, ... Schwarzschild MA, et al. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. Nature Genetics. PMID 33958783 DOI: 10.1038/s41588-021-00847-6  0.557
2021 Zhang X, Molsberry SA, Pavlova M, Schwarzschild MA, Ascherio A, Gao X. Association of Sleepwalking and REM Sleep Behavior Disorder With Parkinson Disease in Men. Jama Network Open. 4: e215713. PMID 33847749 DOI: 10.1001/jamanetworkopen.2021.5713  0.31
2021 Tanner CM, Cummings SR, Schwarzschild MA, Brown EG, Dorsey ER, Espay AJ, Galifianakis NB, Goldman SM, Litvan I, Luthra N, McFarland NR, Mitchell KT, Standaert DG, Bauer DC, Greenspan SL, et al. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism. Npj Parkinson's Disease. 7: 16. PMID 33649343 DOI: 10.1038/s41531-021-00162-1  0.585
2020 Schneider RB, Omberg L, Macklin EA, Daeschler M, Bataille L, Anthwal S, Myers TL, Baloga E, Duquette S, Snyder P, Amodeo K, Tarolli CG, Adams JL, Callahan KF, Gottesman J, ... ... Schwarzschild MA, et al. Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD). Annals of Clinical and Translational Neurology. PMID 33350601 DOI: 10.1002/acn3.51236  0.32
2020 Chen JF, Schwarzschild MA. Do caffeine and more selective adenosine A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease? Parkinsonism & Related Disorders. 45-53. PMID 33349580 DOI: 10.1016/j.parkreldis.2020.10.024  0.392
2020 Simuni T, Fiske B, Merchant K, Coffey CS, Klingner E, Caspell-Garcia C, Lafontant DE, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild M, Weiner D, Adams J, Venuto C, et al. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. Jama Neurology. PMID 33315105 DOI: 10.1001/jamaneurol.2020.4725  0.345
2020 Hung AY, Schwarzschild MA. Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 33205384 DOI: 10.1007/s13311-020-00964-w  0.328
2020 Crotty GF, Maciuca R, Macklin EA, Wang J, Montalban M, Davis SS, Alkabsh JI, Bakshi R, Chen X, Ascherio A, Astarita G, Huntwork-Rodriguez S, Schwarzschild MA. Association of caffeine and related analytes with resistance to Parkinson's disease among mutation carriers: A metabolomic study. Neurology. PMID 32999056 DOI: 10.1212/WNL.0000000000010863  0.316
2020 Schootemeijer S, van der Kolk NM, Ellis T, Mirelman A, Nieuwboer A, Nieuwhof F, Schwarzschild MA, de Vries NM, Bloem BR. Barriers and Motivators to Engage in Exercise for Persons with Parkinson's Disease. Journal of Parkinson's Disease. PMID 32925106 DOI: 10.3233/Jpd-202247  0.373
2020 Molsberry S, Bjornevik K, Hughes KC, Healy B, Schwarzschild M, Ascherio A. Diet pattern and prodromal features of Parkinson's disease. Neurology. PMID 32817391 DOI: 10.1212/Wnl.0000000000010523  0.433
2020 Hasimoglu YG, Chen X, Bakshi R, Schwarzschild MA, Macklin EA. Does Serum Urate Change as Parkinson's Disease Progresses? Journal of Parkinson's Disease. 10: 1571-1576. PMID 32773396 DOI: 10.3233/Jpd-202064  0.446
2020 Ma C, Molsberry S, Li Y, Schwarzschild M, Ascherio A, Gao X. Dietary nicotine intake and risk of Parkinson disease: a prospective study. The American Journal of Clinical Nutrition. PMID 32725131 DOI: 10.1093/Ajcn/Nqaa186  0.438
2020 Crotty GF, Schwarzschild MA. Chasing Protection in Parkinson's Disease: Does Exercise Reduce Risk and Progression? Frontiers in Aging Neuroscience. 12: 186. PMID 32636740 DOI: 10.3389/Fnagi.2020.00186  0.452
2020 Huh YE, Ruby Chiang MS, Locascio JJ, Liao Z, Liu G, Choudhury K, Kuras YI, Tuncali I, Videnovic A, Hunt AL, Schwarzschild MA, Hung AY, Herrington TM, Hayes MT, Hyman BT, et al. β-Glucocerebrosidase Activity in -linked Parkinson's Disease: The Type of Mutation Matters. Neurology. PMID 32540937 DOI: 10.1212/Wnl.0000000000009989  0.62
2020 Palacios N, O'Reilly ÉJ, Schwarzschild MA, Ascherio A. Long-Term Use of Antibiotics and Risk of Parkinson's Disease in the Nurses' Health Study. Parkinson's Disease. 2020: 4038375. PMID 32399169 DOI: 10.1155/2020/4038375  0.382
2020 Bakshi R, Macklin EA, Hung AY, Hayes MT, Hyman BT, Wills AM, Gomperts SN, Growdon JH, Ascherio A, Scherzer CR, Schwarzschild MA. Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study. Journal of Parkinson's Disease. 10: 505-510. PMID 32250320 DOI: 10.3233/Jpd-191882  0.67
2020 Molsberry S, Bjornevik K, Hughes KC, Zhang ZJ, Jeanfavre S, Clish C, Healy B, Schwarzschild M, Ascherio A. Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson's Disease. Journal of Parkinson's Disease. PMID 32250318 DOI: 10.3233/Jpd-191896  0.347
2020 Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, et al. Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Neurology. PMID 32102975 DOI: 10.1212/Wnl.0000000000009107  0.472
2020 Bjornevik K, Schwarzschild MA, Ascherio A. Big health data and Parkinson's disease epidemiology: Challenges and opportunities. Parkinsonism & Related Disorders. 71: 58-59. PMID 31948788 DOI: 10.1016/J.Parkreldis.2020.01.001  0.367
2019 Hughes KC, Gao X, Molsberry S, Valeri L, Schwarzschild MA, Ascherio A. Physical activity and prodromal features of Parkinson disease. Neurology. PMID 31719136 DOI: 10.1212/Wnl.0000000000008567  0.35
2019 Alcalay RN, Kehoe C, Shorr E, Battista R, Hall A, Simuni T, Marder K, Wills AM, Naito A, Beck JC, Schwarzschild MA, Nance M. Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 31680121 DOI: 10.1038/S41436-019-0684-X  0.38
2019 Schwarzschild MA, Macklin EA, Bakshi R, Battacharyya S, Logan R, Espay AJ, Hung AY, Bwala G, Goetz CG, Russell DS, Goudreau JL, Parashos SA, Saint-Hilaire MH, Rudolph A, Hare JM, et al. Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial. Neurology. PMID 31484712 DOI: 10.1212/Wnl.0000000000008194  0.439
2019 Bakshi R, Macklin EA, Logan R, Zorlu MM, Xia N, Crotty GF, Zhang E, Chen X, Ascherio A, Schwarzschild MA. Higher urate in LRRK2 mutation carriers resistant to Parkinson's disease. Annals of Neurology. PMID 30761591 DOI: 10.1002/Ana.25436  0.446
2019 Espay AJ, Vizcarra JA, Marsili L, Lang AE, Simon DK, Merola A, Josephs KA, Fasano A, Morgante F, Savica R, Greenamyre JT, Cambi F, Yamasaki TR, Tanner CM, Gan-Or Z, ... ... Schwarzschild MA, et al. Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology. 92: 329-337. PMID 30745444 DOI: 10.1212/Wnl.0000000000006926  0.383
2019 Ascherio A, Schwarzschild MA. Lifestyle and Parkinson's disease progression. Movement Disorders : Official Journal of the Movement Disorder Society. 34: 7-8. PMID 30653733 DOI: 10.1002/Mds.27566  0.427
2018 Chen X, Umeh CC, Tainsh RE, Feng DD, Maguire M, Zuo F, Rahimian M, Logan R, Wang X, Ascherio A, Macklin EA, Buys ES, Schwarzschild MA. Dissociation between urate and blood pressure in mice and in people with early Parkinson's disease. Ebiomedicine. PMID 30415890 DOI: 10.1016/J.Ebiom.2018.10.039  0.432
2018 Palacios N, Hughes KC, Cereda E, Schwarzschild MA, Ascherio A. Appendectomy and risk of Parkinson's disease in two large prospective cohorts of men and women. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30218460 DOI: 10.1002/Mds.109  0.43
2018 Iwaki H, Hughes KC, Gao X, Schwarzschild MA, Ascherio A. The association between restless legs syndrome and premotor symptoms of Parkinson's disease. Journal of the Neurological Sciences. 394: 41-44. PMID 30212740 DOI: 10.1016/J.Jns.2018.08.028  0.424
2018 Hughes KC, Gao X, Baker JM, Stephen C, Kim IY, Valeri L, Schwarzschild MA, Ascherio A. Non-motor features of Parkinson's disease in a nested case-control study of US men. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 30076266 DOI: 10.1136/Jnnp-2018-318275  0.425
2018 Hughes KC, Gao X, O'Reilly EJ, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Genetic variants related to urate and risk of Parkinson's disease. Parkinsonism & Related Disorders. PMID 29789205 DOI: 10.1016/J.Parkreldis.2018.04.031  0.484
2018 Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, Hannan MT, Betensky RA, Ascherio A. Integration of risk factors for Parkinson disease in 2 large longitudinal cohorts. Neurology. PMID 29643081 DOI: 10.1212/Wnl.0000000000005473  0.47
2018 Cai W, Feng D, Schwarzschild MA, McLean PJ, Chen X. Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice. Ebiomedicine. PMID 29433982 DOI: 10.1016/J.Ebiom.2018.01.035  0.676
2018 Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, McCullough ML, Hannan MT, Betensky RA, Ascherio A. Interaction between caffeine and polymorphisms of glutamate ionotropic receptor NMDA type subunit 2A (GRIN2A) and cytochrome P450 1A2 (CYP1A2) on Parkinson's disease risk. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 29318639 DOI: 10.1002/Mds.27279  0.384
2017 Kim IY, O'Reilly ÉJ, Hughes KC, Gao X, Schwarzschild MA, Ascherio A. Differences in Parkinson's Disease Risk with Caffeine Intake and Postmenopausal Hormone Use. Journal of Parkinson's Disease. PMID 28984617 DOI: 10.3233/Jpd-171175  0.452
2017 Ascherio A, Schwarzschild MA. Dietary antioxidants and Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 32: 1501-1503. PMID 28976040 DOI: 10.1002/Mds.27194  0.411
2017 Crotty GF, Ascherio A, Schwarzschild MA. Targeting urate to reduce oxidative stress in Parkinson disease. Experimental Neurology. 298: 210-224. PMID 28622913 DOI: 10.1016/J.Expneurol.2017.06.017  0.456
2017 Hughes KC, Gao X, Kim IY, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Intake of dairy foods and risk of Parkinson disease. Neurology. PMID 28596209 DOI: 10.1212/Wnl.0000000000004057  0.44
2017 Chen X, Feng D, Schwarzschild MA, Gao X. Red hair, MC1R variants, and risk for Parkinson's disease - a meta-analysis. Annals of Clinical and Translational Neurology. 4: 212-216. PMID 28275654 DOI: 10.1002/Acn3.381  0.423
2017 Espay AJ, Schwarzschild MA, Tanner CM, Fernandez HH, Simon DK, Leverenz JB, Merola A, Chen-Plotkin A, Brundin P, Kauffman MA, Erro R, Kieburtz K, Woo D, Macklin EA, Standaert DG, et al. Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 28233927 DOI: 10.1002/Mds.26913  0.473
2016 Chen X, Chen H, Cai W, Maguire M, Ya B, Zuo F, Logan R, Li H, Robinson K, Vanderburg CR, Yu Y, Wang Y, Fisher DE, Schwarzschild MA. The melanoma-linked "redhead" MC1R influences dopaminergic neuron survival. Annals of Neurology. PMID 28019657 DOI: 10.1002/Ana.24852  0.42
2016 Paganoni S, Schwarzschild MA. Urate as a Marker of Risk and Progression of Neurodegenerative Disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. PMID 27995438 DOI: 10.1007/S13311-016-0497-4  0.491
2016 Hughes KC, Gao X, Kim IY, Rimm EB, Wang M, Weisskopf MG, Schwarzschild MA, Ascherio A. Intake of antioxidant vitamins and risk of parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 27787934 DOI: 10.1002/Mds.26819  0.406
2016 Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. The Lancet. Neurology. 15: 1257-1272. PMID 27751556 DOI: 10.1016/S1474-4422(16)30230-7  0.427
2016 Xu K, Luca DG, Orrú M, Xu Y, Chen JF, Schwarzschild MA. Neuroprotection by caffeine in the MPTP model of Parkinson's disease and its dependence on adenosine A2A receptors. Neuroscience. PMID 26905951 DOI: 10.1016/J.Neuroscience.2016.02.035  0.442
2016 Bhattacharyya S, Bakshi R, Logan R, Ascherio A, Macklin EA, Schwarzschild MA. Oral Inosine Persistently Elevates Plasma antioxidant capacity in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 26805433 DOI: 10.1002/Mds.26483  0.417
2016 Gao X, O'Reilly ÉJ, Schwarzschild MA, Ascherio A. Prospective study of plasma urate and risk of Parkinson disease in men and women. Neurology. PMID 26764029 DOI: 10.1212/Wnl.0000000000002351  0.461
2016 Schwarzschild M, Fitzgerald K, Bakshi R, Macklin E, Scherzer C, Ascherio A. Association of α-synuclein gene expression with Parkinson’s disease is attenuated with higher serum urate in the PPMI cohort Parkinsonism & Related Disorders. 22: e115. DOI: 10.1016/J.Parkreldis.2015.10.265  0.316
2015 Bakshi R, Zhang H, Logan R, Joshi I, Xu Y, Chen X, Schwarzschild MA. Neuroprotective effects of urate are mediated by augmenting astrocytic glutathione synthesis and release. Neurobiology of Disease. PMID 26341543 DOI: 10.1016/J.Nbd.2015.08.022  0.39
2015 Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, et al. Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain : a Journal of Neurology. 138: 2659-71. PMID 26220939 DOI: 10.1093/Brain/Awv202  0.65
2015 Chen X, Wales P, Quinti L, Zuo F, Moniot S, Herisson F, Rauf NA, Wang H, Silverman RB, Ayata C, Maxwell MM, Steegborn C, Schwarzschild MA, Outeiro TF, Kazantsev AG. The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia. Plos One. 10: e0116919. PMID 25608039 DOI: 10.1371/Journal.Pone.0116919  0.416
2015 Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, et al. Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease Brain. 138: 2659-2671. DOI: 10.1093/brain/awv202  0.589
2014 Palacios N, Fitzgerald KC, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A, Laden F. Particulate matter and risk of Parkinson disease in a large prospective study of women. Environmental Health : a Global Access Science Source. 13: 80. PMID 25294559 DOI: 10.1186/1476-069X-13-80  0.389
2014 Simon KC, Eberly S, Gao X, Oakes D, Tanner CM, Shoulson I, Fahn S, Schwarzschild MA, Ascherio A. Mendelian randomization of serum urate and parkinson disease progression. Annals of Neurology. 76: 862-8. PMID 25257975 DOI: 10.1002/Ana.24281  0.454
2014 Palacios N, Fitzgerald K, Roberts AL, Hart JE, Weisskopf MG, Schwarzschild MA, Ascherio A, Laden F. A prospective analysis of airborne metal exposures and risk of Parkinson disease in the nurses' health study cohort. Environmental Health Perspectives. 122: 933-8. PMID 24905870 DOI: 10.1289/Ehp.1307218  0.406
2014 Cipriani S, Bakshi R, Schwarzschild MA. Protection by inosine in a cellular model of Parkinson's disease. Neuroscience. 274: 242-9. PMID 24880154 DOI: 10.1016/J.Neuroscience.2014.05.038  0.386
2014 Kachroo A, Schwarzschild MA. Allopurinol reduces levels of urate and dopamine but not dopaminergic neurons in a dual pesticide model of Parkinson's disease. Brain Research. 1563: 103-9. PMID 24680743 DOI: 10.1016/J.Brainres.2014.03.031  0.417
2014 Wong JC, Li Y, Schwarzschild MA, Ascherio A, Gao X. Restless legs syndrome: an early clinical feature of Parkinson disease in men. Sleep. 37: 369-72. PMID 24497665 DOI: 10.5665/Sleep.3416  0.418
2014 McFarland NR, Dimant H, Kibuuka L, Ebrahimi-Fakhari D, Desjardins CA, Danzer KM, Danzer M, Fan Z, Schwarzschild MA, Hirst W, McLean PJ. Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss. Plos One. 9: e86048. PMID 24465863 DOI: 10.1371/Journal.Pone.0086048  0.717
2014 Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, Hooper DC, Kieburtz KD, Macklin EA, Oakes D, Rudolph A, Shoulson I, Tennis MK, Espay AJ, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. Jama Neurology. 71: 141-50. PMID 24366103 DOI: 10.1001/Jamaneurol.2013.5528  0.421
2014 Hung AY, Schwarzschild MA. Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 11: 34-46. PMID 24310604 DOI: 10.1007/S13311-013-0239-9  0.432
2013 Ding H, Dhima K, Lockhart KC, Locascio JJ, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Hayes MT, Sohur US, Wills AM, Mollenhauer B, Flaherty AW, Hung AY, Mejia N, Khurana V, ... ... Schwarzschild MA, et al. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 81: 1531-7. PMID 24068787 DOI: 10.1212/Wnl.0B013E3182A95818  0.629
2013 Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburtz K, Lees AJ, Schwarzschild MA, Tanner CM, Isaacs T, Duffen J, Matthews H, Wyse RK. Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. Journal of Parkinson's Disease. 3: 231-9. PMID 24018336 DOI: 10.3233/Jpd-139000  0.426
2013 McFarland NR, Burdett T, Desjardins CA, Frosch MP, Schwarzschild MA. Postmortem brain levels of urate and precursors in Parkinson's disease and related disorders. Neuro-Degenerative Diseases. 12: 189-98. PMID 23467193 DOI: 10.1159/000346370  0.682
2013 Wills AM, Eberly S, Tennis M, Lang AE, Messing S, Togasaki D, Tanner CM, Kamp C, Chen JF, Oakes D, McDermott MP, Schwarzschild MA. Caffeine consumption and risk of dyskinesia in CALM-PD. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 380-3. PMID 23339054 DOI: 10.1002/Mds.25319  0.44
2013 Chen X, Burdett TC, Desjardins CA, Logan R, Cipriani S, Xu Y, Schwarzschild MA. Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America. 110: 300-5. PMID 23248282 DOI: 10.1073/Pnas.1217296110  0.456
2013 Burdett TC, Desjardins CA, Logan R, McFarland NR, Chen X, Schwarzschild MA. Efficient determination of purine metabolites in brain tissue and serum by high-performance liquid chromatography with electrochemical and UV detection. Biomedical Chromatography : Bmc. 27: 122-9. PMID 22674671 DOI: 10.1002/Bmc.2760  0.575
2013 McFarland NR, Burdett T, Desjardins CA, Frosch MP, Schwarzschild MA, Nocker M, Scherfler C, Kiechl S, Willeit J, Schmidauer C, Gasperi A, Rungger G, Poewe W, Mahlknecht P, Seppi K, et al. Contents Vol. 12, 2013 Neurodegenerative Diseases. 12. DOI: 10.1159/000355887  0.546
2012 Palacios N, Gao X, Schwarzschild M, Ascherio A. Declining quality of life in Parkinson disease before and after diagnosis. Journal of Parkinson's Disease. 2: 153-60. PMID 23939439 DOI: 10.3233/Jpd-2012-12083  0.378
2012 Gao X, Simon KC, Schwarzschild MA, Ascherio A. Age, statin use, and the risk for incident Parkinson disease-reply. Archives of Neurology. 69: 1381. PMID 23754004 DOI: 10.1001/Archneurol.2012.2032  0.369
2012 Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1392-7. PMID 22976926 DOI: 10.1002/Mds.25157  0.39
2012 Palacios N, Gao X, McCullough ML, Schwarzschild MA, Shah R, Gapstur S, Ascherio A. Caffeine and risk of Parkinson's disease in a large cohort of men and women. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1276-82. PMID 22927157 DOI: 10.1002/Mds.25076  0.412
2012 Schwarzschild MA. Caffeine in Parkinson disease: better for cruise control than snooze patrol? Neurology. 79: 616-8. PMID 22855870 DOI: 10.1212/Wnl.0B013E318263580E  0.392
2012 Palacios N, Gao X, O'Reilly E, Schwarzschild M, McCullough ML, Mayo T, Gapstur SM, Ascherio AA. Alcohol and risk of Parkinson's disease in a large, prospective cohort of men and women. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 980-7. PMID 22714720 DOI: 10.1002/Mds.25050  0.337
2012 Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Protection of dopaminergic cells by urate requires its accumulation in astrocytes. Journal of Neurochemistry. 123: 172-81. PMID 22671773 DOI: 10.1111/J.1471-4159.2012.07820.X  0.337
2012 Cipriani S, Desjardins CA, Burdett TC, Xu Y, Xu K, Schwarzschild MA. Urate and its transgenic depletion modulate neuronal vulnerability in a cellular model of Parkinson's disease. Plos One. 7: e37331. PMID 22606360 DOI: 10.1371/Journal.Pone.0037331  0.333
2012 Chen X, Wu G, Schwarzschild MA. Urate in Parkinson's disease: more than a biomarker? Current Neurology and Neuroscience Reports. 12: 367-75. PMID 22580741 DOI: 10.1007/S11910-012-0282-7  0.494
2012 Gao X, Cassidy A, Schwarzschild MA, Rimm EB, Ascherio A. Habitual intake of dietary flavonoids and risk of Parkinson disease. Neurology. 78: 1138-45. PMID 22491871 DOI: 10.1212/Wnl.0B013E31824F7Fc4  0.409
2012 Gao X, Simon KC, Schwarzschild MA, Ascherio A. Prospective study of statin use and risk of Parkinson disease. Archives of Neurology. 69: 380-4. PMID 22410446 DOI: 10.1001/Archneurol.2011.1060  0.438
2012 Kachroo A, Schwarzschild MA. Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease. Annals of Neurology. 71: 278-82. PMID 22367999 DOI: 10.1002/Ana.22630  0.445
2012 Palacios N, Gao X, Schwarzschild M, Ascherio A. Declining Quality of Life in Parkinson Disease Patients before and after Diagnosis (P06.064) Neurology. 78: P06.064-P06.064. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P06.064  0.315
2012 Palacios N, Roberts A, Weisskopf M, Schwarzschild M, Laden F, Ascherio A. E-002: Exposure to Airborne Metals and risk of Parkinson Disease in a Prospective Study of US Women Epidemiology. 23: 1. DOI: 10.1097/01.Ede.0000416602.63176.B5  0.328
2012 Chen X, Burdett T, Desjardins C, Xu Y, Schwarzschild MA. 3.245 Effects Of Urate Oxidase Transgene Or Knockout In A Mouse Model Of Parkinson'S Disease Parkinsonism & Related Disorders. 18. DOI: 10.1016/S1353-8020(11)70917-8  0.408
2012 Gao X, Simon K, Schwarzschild M, Ascherio A. 1.120 A PROSPECTIVE STUDY OF STATIN USE AND RISK OF PARKINSON DISEASE Parkinsonism & Related Disorders. 18: S40. DOI: 10.1016/S1353-8020(11)70234-6  0.401
2011 Ding H, Sarokhan AK, Roderick SS, Bakshi R, Maher NE, Ashourian P, Kan CG, Chang S, Santarlasci A, Swords KE, Ravina BM, Hayes MT, Sohur US, Wills AM, Flaherty AW, ... ... Schwarzschild MA, et al. Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 2283-6. PMID 21953863 DOI: 10.1002/Mds.23934  0.645
2011 Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H. Serum cholesterol and the progression of parkinson's disease: Results from DATATOP Plos One. 6. PMID 21853051 DOI: 10.1371/Journal.Pone.0022854  0.45
2011 Palacios N, Gao X, McCullough ML, Jacobs EJ, Patel AV, Mayo T, Schwarzschild MA, Ascherio A. Obesity, diabetes, and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 2253-9. PMID 21739472 DOI: 10.1002/Mds.23855  0.372
2011 Gao X, Chen H, Schwarzschild MA, Ascherio A. A prospective study of bowel movement frequency and risk of Parkinson's disease. American Journal of Epidemiology. 174: 546-51. PMID 21719744 DOI: 10.1093/Aje/Kwr119  0.337
2011 Schwarzschild MA, Marek K, Eberly S, Oakes D, Shoulson I, Jennings D, Seibyl J, Ascherio A. Serum urate and probability of dopaminergic deficit in early "Parkinson's disease". Movement Disorders : Official Journal of the Movement Disorder Society. 26: 1864-8. PMID 21538532 DOI: 10.1002/Mds.23741  0.396
2011 Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology. 76: 863-9. PMID 21368281 DOI: 10.1212/Wnl.0B013E31820F2D79  0.45
2011 Barkhoudarian MT, Schwarzschild MA. Preclinical jockeying on the translational track of adenosine A2A receptors. Experimental Neurology. 228: 160-4. PMID 21211537 DOI: 10.1016/J.Expneurol.2010.12.022  0.392
2011 Xiao D, Cassin JJ, Healy B, Burdett TC, Chen JF, Fredholm BB, Schwarzschild MA. Deletion of adenosine A₁ or A(â‚‚A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease. Brain Research. 1367: 310-8. PMID 20828543 DOI: 10.1016/J.Brainres.2010.08.099  0.409
2010 Cipriani S, Chen X, Schwarzschild MA. Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomarkers in Medicine. 4: 701-12. PMID 20945982 DOI: 10.2217/Bmm.10.94  0.478
2010 Black YD, Xiao D, Pellegrino D, Kachroo A, Brownell AL, Schwarzschild MA. Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease. Neuroscience Letters. 486: 161-5. PMID 20854878 DOI: 10.1016/J.Neulet.2010.09.043  0.426
2010 Gardener H, Gao X, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A. Prenatal and early life factors and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1560-7. PMID 20740569 DOI: 10.1002/Mds.23339  0.422
2010 Gao X, Schwarzschild MA, O'Reilly EJ, Wang H, Ascherio A. Restless legs syndrome and Parkinson's disease in men. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 2654-7. PMID 20737545 DOI: 10.1002/Mds.23256  0.445
2010 Morelli M, Carta AR, Kachroo A, Schwarzschild MA. Pathophysiological roles for purines: adenosine, caffeine and urate. Progress in Brain Research. 183: 183-208. PMID 20696321 DOI: 10.1016/S0079-6123(10)83010-9  0.473
2010 O'Reilly EJ, Gao X, Weisskopf MG, Chen H, Schwarzschild MA, Spiegelman D, Ascherio A. Plasma urate and Parkinson's disease in women. American Journal of Epidemiology. 172: 666-70. PMID 20682521 DOI: 10.1093/Aje/Kwq195  0.339
2010 Simon KC, Gao X, Chen H, Schwarzschild MA, Ascherio A. Calcium channel blocker use and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1818-22. PMID 20669249 DOI: 10.1002/Mds.23191  0.452
2010 Palacios N, Weisskopf M, Simon K, Gao X, Schwarzschild M, Ascherio A. Polymorphisms of caffeine metabolism and estrogen receptor genes and risk of Parkinson's disease in men and women. Parkinsonism & Related Disorders. 16: 370-5. PMID 20304699 DOI: 10.1016/J.Parkreldis.2010.02.012  0.403
2010 Kachroo A, Irizarry MC, Schwarzschild MA. Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Experimental Neurology. 223: 657-61. PMID 20188092 DOI: 10.1016/J.Expneurol.2010.02.007  0.446
2010 Schwarzschild MA. Rasagiline in Parkinson's disease. The New England Journal of Medicine. 362: 658; author reply 65. PMID 20187261  0.317
2010 Xu K, Xu YH, Chen JF, Schwarzschild MA. Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience. 167: 475-81. PMID 20167258 DOI: 10.1016/J.Neuroscience.2010.02.020  0.41
2009 Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. Neurology. 73: 1286-91. PMID 19841380 DOI: 10.1212/Wnl.0B013E3181Bd13A1  0.449
2009 Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kieburtz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal MF, Lang AE, ... ... Schwarzschild MA, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Archives of Neurology. 66: 1460-8. PMID 19822770 DOI: 10.1001/Archneurol.2009.247  0.409
2009 Carta AR, Kachroo A, Schintu N, Xu K, Schwarzschild MA, Wardas J, Morelli M. Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. Journal of Neurochemistry. 111: 1478-89. PMID 19817968 DOI: 10.1111/J.1471-4159.2009.06425.X  0.445
2009 McFarland NR, Fan Z, Xu K, Schwarzschild MA, Feany MB, Hyman BT, McLean PJ. Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. Journal of Neuropathology and Experimental Neurology. 68: 515-24. PMID 19525899 DOI: 10.1097/Nen.0B013E3181A24B53  0.738
2009 Simon KC, Chen H, Gao X, Schwarzschild MA, Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 1359-65. PMID 19424986 DOI: 10.1002/Mds.22619  0.441
2009 Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Genetic determinants of hair color and Parkinson's disease risk. Annals of Neurology. 65: 76-82. PMID 19194882 DOI: 10.1002/Ana.21535  0.463
2009 Bronstein J, Carvey P, Chen H, Cory-Slechta D, DiMonte D, Duda J, English P, Goldman S, Grate S, Hansen J, Hoppin J, Jewell S, Kamel F, Koroshetz W, Langston JW, ... ... Schwarzschild M, et al. Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference 26-28 June 2007. Environmental Health Perspectives. 117: 117-21. PMID 19165397 DOI: 10.1289/Ehp.11702  0.463
2009 O'Reilly EJ, Chen H, Gardener H, Gao X, Schwarzschild MA, Ascherio A. Smoking and Parkinson's disease: using parental smoking as a proxy to explore causality. American Journal of Epidemiology. 169: 678-82. PMID 19131566 DOI: 10.1093/Aje/Kwn388  0.35
2009 Petzer JP, Castagnoli N, Schwarzschild MA, Chen JF, Van der Schyf CJ. Dual-target-directed drugs that block monoamine oxidase B and adenosine A(2A) receptors for Parkinson's disease. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 6: 141-51. PMID 19110205 DOI: 10.1016/J.Nurt.2008.10.035  0.419
2008 Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A, Hyson C, Gorbold E, Rudolph A, Kieburtz K, Fahn S, Gauger L, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Archives of Neurology. 65: 716-23. PMID 18413464 DOI: 10.1001/Archneur.2008.65.6.Nct70003  0.438
2008 Gao X, Chen H, Choi HK, Curhan G, Schwarzschild MA, Ascherio A. Diet, urate, and Parkinson's disease risk in men. American Journal of Epidemiology. 167: 831-8. PMID 18326873 DOI: 10.1093/Aje/Kwm385  0.454
2008 Gao X, Chen H, Schwarzschild MA, Logroscino G, Ascherio A. Perceived imbalance and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 613-6. PMID 18181208 DOI: 10.1002/Mds.21919  0.472
2008 Wang H, Chen H, Gao X, McGrath M, Deer D, De Vivo I, Schwarzschild MA, Ascherio A. Telomere length and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 302-5. PMID 18044760 DOI: 10.1002/Mds.21867  0.459
2008 Thacker EL, Chen H, Patel AV, McCullough ML, Calle EE, Thun MJ, Schwarzschild MA, Ascherio A. Recreational physical activity and risk of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 69-74. PMID 17960818 DOI: 10.1002/Mds.21772  0.42
2008 Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. American Journal of Epidemiology. 167: 90-5. PMID 17890755 DOI: 10.1093/Aje/Kwm260  0.357
2008 McFarland NR, Schwarzschild MA. Is Mortality Increased with Essential Tremor Nejm Journal Watch. 2008. DOI: 10.1056/Jn200803110000003  0.57
2007 Schwarzschild MA. Adenosine A2A antagonists as neurotherapeutics: crossing the bridge. Progress in Neurobiology. 83: 261-2. PMID 17997007 DOI: 10.1016/J.Pneurobio.2007.10.002  0.342
2007 Gao X, Chen H, Fung TT, Logroscino G, Schwarzschild MA, Hu FB, Ascherio A. Prospective study of dietary pattern and risk of Parkinson disease. The American Journal of Clinical Nutrition. 86: 1486-94. PMID 17991663 DOI: 10.1093/Ajcn/86.5.1486  0.417
2007 Gao X, Chen H, Schwarzschild MA, Glasser DB, Logroscino G, Rimm EB, Ascherio A. Erectile function and risk of Parkinson's disease. American Journal of Epidemiology. 166: 1446-50. PMID 17875583 DOI: 10.1093/Aje/Kwm246  0.379
2007 Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications. Progress in Neurobiology. 83: 293-309. PMID 17826884 DOI: 10.1016/J.Pneurobio.2007.07.001  0.417
2007 Simon KC, Chen H, Schwarzschild M, Ascherio A. Hypertension, hypercholesterolemia, diabetes, and risk of Parkinson disease. Neurology. 69: 1688-95. PMID 17761552 DOI: 10.1212/01.Wnl.0000271883.45010.8A  0.431
2007 Hung AY, Schwarzschild MA. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? Current Opinion in Neurology. 20: 477-83. PMID 17620885 DOI: 10.1097/Wco.0B013E32826388D6  0.385
2007 Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. American Journal of Epidemiology. 166: 561-7. PMID 17584757 DOI: 10.1093/Aje/Kwm127  0.453
2007 Thacker EL, O'Reilly EJ, Weisskopf MG, Chen H, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology. 68: 764-8. PMID 17339584 DOI: 10.1212/01.Wnl.0000256374.50227.4B  0.33
2007 Chen H, O'Reilly E, McCullough ML, Rodriguez C, Schwarzschild MA, Calle EE, Thun MJ, Ascherio A. Consumption of dairy products and risk of Parkinson's disease. American Journal of Epidemiology. 165: 998-1006. PMID 17272289 DOI: 10.1093/Aje/Kwk089  0.32
2007 Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR. Molecular markers of early Parkinson's disease based on gene expression in blood. Proceedings of the National Academy of Sciences of the United States of America. 104: 955-60. PMID 17215369 DOI: 10.1073/Pnas.0610204104  0.623
2006 Xiao D, Bastia E, Xu YH, Benn CL, Cha JH, Peterson TS, Chen JF, Schwarzschild MA. Forebrain adenosine A2A receptors contribute to L-3,4-dihydroxyphenylalanine-induced dyskinesia in hemiparkinsonian mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 13548-55. PMID 17192438 DOI: 10.1523/Jneurosci.3554-06.2006  0.407
2006 Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M. Targeting adenosine A2A receptors in Parkinson's disease. Trends in Neurosciences. 29: 647-54. PMID 17030429 DOI: 10.1016/J.Tins.2006.09.004  0.466
2006 Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nature Reviews. Drug Discovery. 5: 845-54. PMID 17016425 DOI: 10.1038/Nrd2087  0.41
2006 Ascherio A, Chen H, Weisskopf MG, O'Reilly E, McCullough ML, Calle EE, Schwarzschild MA, Thun MJ. Pesticide exposure and risk for Parkinson's disease. Annals of Neurology. 60: 197-203. PMID 16802290 DOI: 10.1002/Ana.20904  0.447
2006 Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Ascherio A. Survival of Parkinson's disease patients in a large prospective cohort of male health professionals. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1002-7. PMID 16602107 DOI: 10.1002/Mds.20881  0.458
2006 Chen H, Schernhammer E, Schwarzschild MA, Ascherio A. A prospective study of night shift work, sleep duration, and risk of Parkinson's disease. American Journal of Epidemiology. 163: 726-30. PMID 16495472 DOI: 10.1093/Aje/Kwj096  0.319
2006 Xu K, Xu Y, Brown-Jermyn D, Chen JF, Ascherio A, Dluzen DE, Schwarzschild MA. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 535-41. PMID 16407551 DOI: 10.1523/Jneurosci.3008-05.2006  0.438
2006 Yu L, Schwarzschild MA, Chen JF. Cross-sensitization between caffeine- and L-dopa-induced behaviors in hemiparkinsonian mice. Neuroscience Letters. 393: 31-5. PMID 16236444 DOI: 10.1016/J.Neulet.2005.09.036  0.33
2006 Weisskopf MG, O'Reilly E, McCullough ML, Calle EE, Thun MJ, Schwarzschild MA, Ascherio A. Prospective Study Of Education, Occupation, and Risk of Parkinson's Disease American Journal of Epidemiology. 163. DOI: 10.1093/Aje/163.Suppl_11.S178-C  0.375
2005 Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, Ascherio A. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease. Annals of Neurology. 58: 963-7. PMID 16240369 DOI: 10.1002/Ana.20682  0.451
2005 Hauser RA, Schwarzschild MA. Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs & Aging. 22: 471-482. PMID 15974638 DOI: 10.2165/00002512-200522060-00002  0.481
2005 Xu K, Bastia E, Schwarzschild M. Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. Pharmacology & Therapeutics. 105: 267-310. PMID 15737407 DOI: 10.1016/J.Pharmthera.2004.10.007  0.423
2005 Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Ascherio A. Physical activity and the risk of Parkinson disease Neurology. 64: 664-669. PMID 15728289 DOI: 10.1212/01.Wnl.0000151960.28687.93  0.442
2004 Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Logroscino G, Willett WC, Ascherio A. Folate Intake and Risk of Parkinson’s Disease American Journal of Epidemiology. 160: 368-375. PMID 15286022 DOI: 10.1093/Aje/Kwh213  0.4
2004 Chen H, Zhang SM, Schwarzschild MA, Hernán MA, Willett WC, Ascherio A. Obesity and the Risk of Parkinson’s Disease American Journal of Epidemiology. 159: 547-555. PMID 15003958 DOI: 10.1093/Aje/Kwh059  0.422
2004 Dunah AW, Sirianni AC, Fienberg AA, Bastia E, Schwarzschild MA, Standaert DG. Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32. Molecular Pharmacology. 65: 121-9. PMID 14722243 DOI: 10.1124/Mol.65.1.121  0.32
2003 Chen JF, Fredduzzi S, Bastia E, Yu L, Moratalla R, Ongini E, Schwarzschild MA. Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease. Neurology. 61: S74-81. PMID 14663016 DOI: 10.1212/01.Wnl.0000095218.26363.7B  0.423
2003 Castagnoli N, Petzer JP, Steyn S, Castagnoli K, Chen JF, Schwarzschild MA, Van der Schyf CJ. Monoamine oxidase B inhibition and neuroprotection: studies on selective adenosine A2A receptor antagonists. Neurology. 61: S62-8. PMID 14663013 DOI: 10.1212/01.Wnl.0000095215.97585.59  0.437
2003 Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, Castagnoli N, Chen JF. Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease. Neurology. 61: S55-61. PMID 14663012 DOI: 10.1212/01.Wnl.0000095214.53646.72  0.471
2003 Chen J, Chase T, Schwarzschild M. J. Stephen Fink, MD, PhD (1950–2002) Neurology. 61. PMID 14663000 DOI: 10.1212/01.Wnl.0000095201.55121.8A  0.381
2003 Bibbiani F, Oh JD, Petzer JP, Castagnoli N, Chen JF, Schwarzschild MA, Chase TN. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Experimental Neurology. 184: 285-94. PMID 14637099 DOI: 10.1016/S0014-4886(03)00250-4  0.387
2003 Chen H, Zhang SM, Hernán MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A. Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease Jama Neurology. 60: 1059-1064. PMID 12925360 DOI: 10.1001/Archneur.60.8.1059  0.459
2003 Hernán MA, Chen H, Schwarzschild MA, Ascherio A. Alcohol consumption and the incidence of Parkinson's disease Annals of Neurology. 54: 170-175. PMID 12891669 DOI: 10.1002/Ana.10611  0.431
2003 Weisskopf MG, Chen H, Schwarzschild MA, Kawachi I, Ascherio A. Prospective study of phobic anxiety and risk of Parkinson's disease Movement Disorders. 18: 646-651. PMID 12784267 DOI: 10.1002/Mds.10425  0.451
2003 Ascherio A, Chen H, Schwarzschild MA, Zhang SM, Colditz GA, Speizer FE. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease Neurology. 60: 790-795. PMID 12629235 DOI: 10.1212/01.Wnl.0000046523.05125.87  0.399
2003 Petzer JP, Steyn S, Castagnoli KP, Chen JF, Schwarzschild MA, Van der Schyf CJ, Castagnoli N. Inhibition of monoamine oxidase B by selective adenosine A2A receptor antagonists. Bioorganic & Medicinal Chemistry. 11: 1299-310. PMID 12628657 DOI: 10.1016/S0968-0896(02)00648-X  0.375
2003 Gomez-Isla T, Irizarry MC, Mariash A, Cheung B, Soto O, Schrump S, Sondel J, Kotilinek L, Day J, Schwarzschild MA, Cha JH, Newell K, Miller DW, Uéda K, Young AB, et al. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice. Neurobiology of Aging. 24: 245-58. PMID 12498958 DOI: 10.1016/S0197-4580(02)00091-X  0.497
2003 Schwarzschild MA, Chen JF, Chase TN. A2A antagonists for PD: A prime example of translational neuroscience Neurology. 61: S3-S4. DOI: 10.1212/01.Wnl.0000095202.94814.0F  0.438
2003 Chen J, Schwarzschild MA. Gene knockout approach to adenosine A2A receptors in Parkinson's disease Drug Development Research. 58: 354-367. DOI: 10.1002/Ddr.10215  0.39
2002 Chen JF, Steyn S, Staal R, Petzer JP, Xu K, Van Der Schyf CJ, Castagnoli K, Sonsalla PK, Castagnoli N, Schwarzschild MA. 8-(3-Chlorostyryl)caffeine may attenuate MPTP neurotoxicity through dual actions of monoamine oxidase inhibition and A2A receptor antagonism. The Journal of Biological Chemistry. 277: 36040-4. PMID 12130655 DOI: 10.1074/Jbc.M206830200  0.317
2002 Schwarzschild MA, Chen J, Ascherio A. Caffeinated clues and the promise of adenosine A2A antagonists in PD Neurology. 58: 1154-1160. PMID 11971080 DOI: 10.1212/Wnl.58.8.1154  0.461
2002 Xu K, Xu YH, Chen JF, Schwarzschild MA. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. Neuroscience Letters. 322: 13-6. PMID 11958832 DOI: 10.1016/S0304-3940(02)00069-1  0.308
2001 Gearan T, Castillo OA, Schwarzschild MA. The parkinsonian neurotoxin, MPP+ induces phosphorylated c-Jun in dopaminergric neurons of mesencephalic cultures. Parkinsonism & Related Disorders. 8: 19-22. PMID 11472876 DOI: 10.1016/S1353-8020(00)00078-X  0.333
2001 Chen J, Xu K, Petzer JP, Staal R, Xu Y, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N, Schwarzschild MA. Neuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's Disease The Journal of Neuroscience. 21: RC143-RC143. DOI: 10.1523/Jneurosci.21-10-J0001.2001  0.486
2001 Ongini E, Monopoli A, Impagnatiello F, Fredduzzi S, Schwarzschild M, Chen J. Dual actions of A2A adenosine receptor antagonists on motor dysfunction and neurodegenerative processes Drug Development Research. 52: 379-386. DOI: 10.1002/Ddr.1137  0.339
Low-probability matches (unlikely to be authored by this person)
2024 Wyse RK, Isaacs T, Barker RA, Cookson MR, Dawson TM, Devos D, Dexter DT, Duffen J, Federoff H, Fiske B, Foltynie T, Fox S, Greenamyre JT, Kieburtz K, Kordower JH, ... ... Schwarzschild MA, et al. Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials initiative. Journal of Parkinson's Disease. PMID 38578902 DOI: 10.3233/JPD-230363  0.3
2005 Kachroo A, Orlando LR, Grandy DK, Chen JF, Young AB, Schwarzschild MA. Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 10414-9. PMID 16280580 DOI: 10.1523/Jneurosci.3660-05.2005  0.298
2003 Bastia E, Schwarzschild MA. DARPP chocolate: a caffeinated morsel of striatal signaling. Science Signaling. 2003. PMID 12527819 DOI: 10.1126/Stke.2003.165.Pe2  0.298
2010 Schwarzschild MA. The delayed-start study in Parkinson disease: can't satisfy everyone: Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology. 75: 1943-4; author reply. PMID 21098412 DOI: 10.1212/Wnl.0B013E3181Fac7F9  0.297
2017 Palacios N, Fitzgerald KC, Hart JE, Weisskopf M, Schwarzschild MA, Ascherio A, Laden F. Air Pollution and Risk of Parkinson's Disease in a Large Prospective Study of Men. Environmental Health Perspectives. 125: 087011. PMID 28886605 DOI: 10.1289/Ehp259  0.297
2009 Quiroz C, Luján R, Uchigashima M, Simoes AP, Lerner TN, Borycz J, Kachroo A, Canas PM, Orru M, Schwarzschild MA, Rosin DL, Kreitzer AC, Cunha RA, Watanabe M, Ferré S. Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway. Thescientificworldjournal. 9: 1321-44. PMID 19936569 DOI: 10.1100/Tsw.2009.143  0.293
2013 Salamone JD, Collins-Praino LE, Pardo M, Podurgiel SJ, Baqi Y, Müller CE, Schwarzschild MA, Correa M. Conditional neural knockout of the adenosine A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of parkinsonian tremor. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 23: 972-7. PMID 22947264 DOI: 10.1016/J.Euroneuro.2012.08.004  0.292
2023 Flores-Torres MH, Bjornevik K, Hung AY, Healy BC, Schwarzschild MA, Blacker D, Ascherio A. Subjective Cognitive Decline in Women with Features Suggestive of Prodromal Parkinson's Disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 37315105 DOI: 10.1002/mds.29503  0.292
2019 Alcalay RN, Kehoe C, Shorr E, Battista R, Hall A, Simuni T, Marder K, Wills AM, Naito A, Beck JC, Schwarzschild MA, Nance M. Correction: Genetic testing for Parkinson disease: current practice, knowledge, and attitudes among US and Canadian movement disorders specialists. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 31772350 DOI: 10.1038/S41436-019-0709-5  0.292
2024 Rose KN, Schwarzschild MA, Gomperts SN. Clearing the Smoke: What Protects Smokers from Parkinson's Disease? Movement Disorders : Official Journal of the Movement Disorder Society. PMID 38226487 DOI: 10.1002/mds.29707  0.292
2021 Hughes KC, Gao X, Baker JM, Stephen CD, Kim IY, Valeri L, Schwarzschild MA, Ascherio A. Non-Motor Features of Parkinson's Disease in Women. Journal of Parkinson's Disease. PMID 33935102 DOI: 10.3233/JPD-202409  0.291
2002 Fredduzzi S, Moratalla R, Monopoli A, Cuellar B, Xu K, Ongini E, Impagnatiello F, Schwarzschild MA, Chen JF. Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 1054-62. PMID 11826134 DOI: 10.1523/Jneurosci.22-03-01054.2002  0.289
2006 Chan ES, Fernandez P, Merchant AA, Montesinos MC, Trzaska S, Desai A, Tung CF, Khoa DN, Pillinger MH, Reiss AB, Tomic-Canic M, Chen JF, Schwarzschild MA, Cronstein BN. Adenosine A2A receptors in diffuse dermal fibrosis: pathogenic role in human dermal fibroblasts and in a murine model of scleroderma. Arthritis and Rheumatism. 54: 2632-42. PMID 16871530 DOI: 10.1002/Art.21974  0.289
2009 Irizarry MC, Raman R, Schwarzschild MA, Becerra LM, Thomas RG, Peterson RC, Ascherio A, Aisen PS. Plasma urate and progression of mild cognitive impairment. Neuro-Degenerative Diseases. 6: 23-8. PMID 19066433 DOI: 10.1159/000170883  0.286
2005 Huang ZL, Qu WM, Eguchi N, Chen JF, Schwarzschild MA, Fredholm BB, Urade Y, Hayaishi O. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nature Neuroscience. 8: 858-9. PMID 15965471 DOI: 10.1038/Nn1491  0.285
2023 Srivast P, Nishiyama S, Lin SH, Srivast A, Su C, Peng W, Levy M, Schwarzschild M, Xu Y, Chen X. Peripheral MC1R activation modulates immune responses and is neuroprotective in a mouse model of Parkinson's disease. Research Square. PMID 37398302 DOI: 10.21203/rs.3.rs-3042571/v1  0.283
2005 Chen H, Schernhammer E, Schwarzschild MA, Ascherio A. 359: Night Shift Work and Risk of Parkinson's Disease American Journal of Epidemiology. 161: S90-S90. DOI: 10.1093/aje/161.supplement_1.s90b  0.283
2018 Bakshi R, Xu Y, Mueller KA, Chen X, Granucci E, Paganoni S, Sadri-Vakili G, Schwarzschild MA. Urate mitigates oxidative stress and motor neuron toxicity of astrocytes derived from ALS-linked SOD1 mutant mice. Molecular and Cellular Neurosciences. PMID 29928993 DOI: 10.1016/J.Mcn.2018.06.002  0.283
2011 James MJE, Chen PX, Morelli M, Postuma R, Schwarzschild MA. The Putative Neuroprotective Effects of Caffeine Journal of Caffeine Research. 1: 91-96. DOI: 10.1089/Jcr.2011.1207  0.282
2005 Saura J, Angulo E, Ejarque A, Casadó V, Tusell JM, Moratalla R, Chen JF, Schwarzschild MA, Lluis C, Franco R, Serratosa J. Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. Journal of Neurochemistry. 95: 919-29. PMID 16092928 DOI: 10.1111/J.1471-4159.2005.03395.X  0.282
2021 Peters OM, Weiss A, Metterville J, Song L, Logan R, Smith GA, Schwarzschild MA, Mueller C, Brown RH, Freeman M. Genetic diversity of axon degenerative mechanisms in models of Parkinson's disease. Neurobiology of Disease. 105368. PMID 33892050 DOI: 10.1016/j.nbd.2021.105368  0.28
2023 Schootemeijer S, de Vries NM, Macklin EA, Roes KCB, Joosten H, Omberg L, Ascherio A, Schwarzschild MA, Bloem BR. The STEPWISE study: study protocol for a smartphone-based exercise solution for people with Parkinson's Disease (randomized controlled trial). Bmc Neurology. 23: 323. PMID 37700241 DOI: 10.1186/s12883-023-03355-8  0.278
2000 Chen JF, Beilstein M, Xu YH, Turner TJ, Moratalla R, Standaert DG, Aloyo VJ, Fink JS, Schwarzschild MA. Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A(2A) adenosine receptors. Neuroscience. 97: 195-204. PMID 10771351 DOI: 10.1016/S0306-4522(99)00604-1  0.278
2005 Bastia E, Xu YH, Scibelli AC, Day YJ, Linden J, Chen JF, Schwarzschild MA. A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 30: 891-900. PMID 15602504 DOI: 10.1038/Sj.Npp.1300630  0.277
2003 Chen JF, Moratalla R, Yu L, Martín AB, Xu K, Bastia E, Hackett E, Alberti I, Schwarzschild MA. Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 28: 1086-95. PMID 12700712 DOI: 10.1038/Sj.Npp.1300152  0.277
2005 Yu L, Haverty PM, Mariani J, Wang Y, Shen HY, Schwarzschild MA, Weng Z, Chen JF. Genetic and pharmacological inactivation of adenosine A2A receptor reveals an Egr-2-mediated transcriptional regulatory network in the mouse striatum. Physiological Genomics. 23: 89-102. PMID 16046619 DOI: 10.1152/Physiolgenomics.00068.2005  0.275
2004 Fink JS, Kalda A, Ryu H, Stack EC, Schwarzschild MA, Chen JF, Ferrante RJ. Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage. Journal of Neurochemistry. 88: 538-44. PMID 14720203 DOI: 10.1046/J.1471-4159.2003.02145.X  0.275
2017 Quinti L, Dayalan Naidu S, Träger U, Chen X, Kegel-Gleason K, Llères D, Connolly C, Chopra V, Low C, Moniot S, Sapp E, Tousley AR, Vodicka P, Van Kanegan MJ, Kaltenbach LS, ... ... Schwarzschild MA, et al. KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington's disease patients. Proceedings of the National Academy of Sciences of the United States of America. PMID 28533375 DOI: 10.1073/Pnas.1614943114  0.275
2006 Chan ES, Montesinos MC, Fernandez P, Desai A, Delano DL, Yee H, Reiss AB, Pillinger MH, Chen JF, Schwarzschild MA, Friedman SL, Cronstein BN. Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis. British Journal of Pharmacology. 148: 1144-55. PMID 16783407 DOI: 10.1038/Sj.Bjp.0706812  0.275
1999 Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D, Moskowitz MA, Fink JS, Schwarzschild MA. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 19: 9192-200. PMID 10531422 DOI: 10.1523/Jneurosci.19-21-09192.1999  0.272
2017 Schwarzschild MA. Could MAO-B Inhibitor Withdrawal Rather than Nilotinib Benefit Explain the Dopamine Metabolite Increase in Parkinsonian Study Subjects? Journal of Parkinson's Disease. 7: 79-80. PMID 28035939 DOI: 10.3233/Jpd-160975  0.269
2008 Tikh EI, Fenton RA, Chen JF, Schwarzschild MA, Dobson JG. Adenosine A1 and A2A receptor regulation of protein phosphatase 2A in the murine heart. Journal of Cellular Physiology. 216: 83-90. PMID 18181173 DOI: 10.1002/Jcp.21375  0.268
1997 Schwarzschild M, Rordorf G, Bekken K, Buonanno F, Schmahmann JD. Normal-pressure hydrocephalus with misleading features of irreversible dementias : A case report Journal of Geriatric Psychiatry and Neurology. 10: 51-54. PMID 9188018 DOI: 10.1177/089198879701000202  0.266
2005 Tebano MT, Martire A, Rebola N, Pepponi R, Domenici MR, Grò MC, Schwarzschild MA, Chen JF, Cunha RA, Popoli P. Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-D-aspartate effects. Journal of Neurochemistry. 95: 1188-200. PMID 16271052 DOI: 10.1111/J.1471-4159.2005.03455.X  0.265
2000 Apasov SG, Chen JF, Smith PT, Schwarzschild MA, Fink JS, Sitkovsky MV. Study of A(2A) adenosine receptor gene deficient mice reveals that adenosine analogue CGS 21680 possesses no A(2A) receptor-unrelated lymphotoxicity. British Journal of Pharmacology. 131: 43-50. PMID 10960067 DOI: 10.1038/Sj.Bjp.0703532  0.265
2021 Flores-Torres MH, Hughes KC, Molsberry S, Gao X, Kang JH, Schwarzschild MA, Ascherio A. Cognitive function in men with non-motor features of Parkinson's disease. Bmj Neurology Open. 3: e000112. PMID 34250483 DOI: 10.1136/bmjno-2020-000112  0.265
2001 Armstrong JM, Chen JF, Schwarzschild MA, Apasov S, Smith PT, Caldwell C, Chen P, Figler H, Sullivan G, Fink S, Linden J, Sitkovsky M. Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice. The Biochemical Journal. 354: 123-30. PMID 11171087 DOI: 10.1042/0264-6021:3540123  0.262
2002 Montesinos MC, Desai A, Chen JF, Yee H, Schwarzschild MA, Fink JS, Cronstein BN. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. The American Journal of Pathology. 160: 2009-18. PMID 12057906 DOI: 10.1016/S0002-9440(10)61151-0  0.261
1997 Schwarzschild MA, Cole RL, Hyman SE. Glutamate, but not dopamine, stimulates stress-activated protein kinase and AP-1-mediated transcription in striatal neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 17: 3455-66. PMID 9133371 DOI: 10.1523/Jneurosci.17-10-03455.1997  0.261
2022 Darweesh SKL, De Vries NM, Helmich RC, Verbeek MM, Schwarzschild MA, Bloem BR. Inhibition of Neuroinflammation May Mediate the Disease-Modifying Effects of Exercise: Implications for Parkinson's Disease. Journal of Parkinson's Disease. PMID 35466957 DOI: 10.3233/JPD-223216  0.26
2017 O'Reilly ÉJ, Bjornevik K, Schwarzschild MA, McCullough ML, Kolonel LN, Le Marchand L, Manson JE, Ascherio A. Pre-diagnostic plasma urate and the risk of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-7. PMID 29277115 DOI: 10.1080/21678421.2017.1418005  0.257
2016 O'Reilly ÉJ, Liu D, Johns DR, Cudkowicz ME, Paganoni S, Schwarzschild MA, Leitner M, Ascherio A. Serum urate at trial entry and ALS progression in EMPOWER. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-6. PMID 27677562 DOI: 10.1080/21678421.2016.1214733  0.256
2002 Leibovich SJ, Chen JF, Pinhal-Enfield G, Belem PC, Elson G, Rosania A, Ramanathan M, Montesinos C, Jacobson M, Schwarzschild MA, Fink JS, Cronstein B. Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. The American Journal of Pathology. 160: 2231-44. PMID 12057925 DOI: 10.1016/S0002-9440(10)61170-4  0.256
2004 Qu WM, Huang ZL, Mochizuki T, Eguchi N, Chen JF, Schwarzschild MA, Fink SJ, Urade Y, Hayaishi O. Adenosine A2A receptor deficiency attenuates the somnogenic effect of prostaglandin D2 Sleep and Biological Rhythms. 2: S55. DOI: 10.1111/J.1479-8425.2004.00114.X  0.255
2012 Matos M, Augusto E, Santos-Rodrigues AD, Schwarzschild MA, Chen JF, Cunha RA, Agostinho P. Adenosine A2A receptors modulate glutamate uptake in cultured astrocytes and gliosomes. Glia. 60: 702-16. PMID 22298379 DOI: 10.1002/Glia.22290  0.254
2004 Yu L, Frith MC, Suzuki Y, Peterfreund RA, Gearan T, Sugano S, Schwarzschild MA, Weng Z, Fink JS, Chen JF. Characterization of genomic organization of the adenosine A2A receptor gene by molecular and bioinformatics analyses. Brain Research. 1000: 156-73. PMID 15053963 DOI: 10.1016/J.Brainres.2003.11.072  0.254
2001 Chen JF, Moratalla R, Impagnatiello F, Grandy DK, Cuellar B, Rubinstein M, Beilstein MA, Hackett E, Fink JS, Low MJ, Ongini E, Schwarzschild MA. The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice. Proceedings of the National Academy of Sciences of the United States of America. 98: 1970-5. PMID 11172060 DOI: 10.1073/Pnas.98.4.1970  0.253
2008 Tebano MT, Martire A, Potenza RL, Grò C, Pepponi R, Armida M, Domenici MR, Schwarzschild MA, Chen JF, Popoli P. Adenosine A(2A) receptors are required for normal BDNF levels and BDNF-induced potentiation of synaptic transmission in the mouse hippocampus. Journal of Neurochemistry. 104: 279-86. PMID 18005343 DOI: 10.1111/J.1471-4159.2007.05046.X  0.25
2000 Francis JW, Brown RH, Figueiredo D, Remington MP, Castillo O, Schwarzschild MA, Fishman PS, Murphy JR, vanderSpek JC. Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: a potential vector for delivering heterologous proteins to neurons. Journal of Neurochemistry. 74: 2528-36. PMID 10820215 DOI: 10.1046/J.1471-4159.2000.0742528.X  0.247
1999 Schwarzschild MA, Cole RL, Meyers MA, Hyman SE. Contrasting calcium dependencies of SAPK and ERK activations by glutamate in cultured striatal neurons. Journal of Neurochemistry. 72: 2248-55. PMID 10349832 DOI: 10.1046/J.1471-4159.1999.0722248.X  0.245
2023 Flores-Torres MH, Christine CW, Bjornevik K, Molsberry SA, Hung AY, Healy BC, Blacker D, Schwarzschild MA, Ascherio A. Long-Term Intake of Folate, Vitamin B6, and Vitamin B12 and the Incidence of Parkinson's Disease in a Sample of U.S. Women and Men. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 36938854 DOI: 10.1002/mds.29383  0.242
2019 Bjornevik K, Zhang Z, O'Reilly ÉJ, Berry JD, Clish CB, Deik A, Jeanfavre S, Kato I, Kelly RS, Kolonel LN, Liang L, Marchand LL, McCullough ML, Paganoni S, Pierce KA, ... Schwarzschild MA, et al. Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology. PMID 30926684 DOI: 10.1212/Wnl.0000000000007401  0.241
2015 Bakshi R, Logan R, Schwarzschild MA. Purines in parkinson's: Adenosine A2A receptors and urate as targets for neuroprotection The Adenosinergic System: a Non-Dopaminergic Target in Parkinson's Disease. 101-126. DOI: 10.1007/978-3-319-20273-0_6  0.241
2003 Day YJ, Huang L, McDuffie MJ, Rosin DL, Ye H, Chen JF, Schwarzschild MA, Fink JS, Linden J, Okusa MD. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. The Journal of Clinical Investigation. 112: 883-91. PMID 12975473 DOI: 10.1172/Jci15483  0.241
2000 Haskó G, Kuhel DG, Chen JF, Schwarzschild MA, Deitch EA, Mabley JG, Marton A, Szabó C. Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 14: 2065-74. PMID 11023991 DOI: 10.1096/Fj.99-0508Com  0.24
2010 Gao X, Schwarzschild MA, O'Reilly EJ, Wang H, Ascherio A. Restless legs syndrome and erectile dysfunction. Sleep. 33: 75-9. PMID 20120623 DOI: 10.1093/Sleep/33.1.75  0.237
2009 Yang JN, Björklund O, Lindström-Törnqvist K, Lindgren E, Eriksson TM, Kahlström J, Chen JF, Schwarzschild MA, Tobler I, Fredholm BB. Mice heterozygous for both A1 and A(2A) adenosine receptor genes show similarities to mice given long-term caffeine. Journal of Applied Physiology (Bethesda, Md. : 1985). 106: 631-9. PMID 19036889 DOI: 10.1152/Japplphysiol.90971.2008  0.236
2018 Bjornevik K, O'Reilly ÉJ, Berry JD, Clish CB, Jeanfavre S, Kato I, Kolonel LN, Le Marchand L, McCullough ML, Paganoni S, Schwarzschild MA, Talbott EO, Wallace RB, Zhang Z, Manson JE, et al. Prediagnostic plasma branched chain amino acids and the risk of amyotrophic lateral sclerosis. Neurology. PMID 30429276 DOI: 10.1212/Wnl.0000000000006669  0.235
2003 Urade Y, Eguchi N, Qu WM, Sakata M, Huang ZL, Chen JF, Schwarzschild MA, Fink JS, Hayaishi O. Sleep regulation in adenosine A2A receptor-deficient mice. Neurology. 61: S94-6. PMID 14663019 DOI: 10.1212/01.Wnl.0000095222.41066.5E  0.232
2004 Francis JW, Bastia E, Matthews CC, Parks DA, Schwarzschild MA, Brown RH, Fishman PS. Tetanus toxin fragment C as a vector to enhance delivery of proteins to the CNS. Brain Research. 1011: 7-13. PMID 15140640 DOI: 10.1016/J.Brainres.2004.03.007  0.232
1994 Schwarzschild MA, Dauer WT, Lewis SE, Hamill LK, Fink JS, Hyman SE. Leukemia inhibitory factor and ciliary neurotrophic factor increase activated Ras in a neuroblastoma cell line and in sympathetic neuron cultures. Journal of Neurochemistry. 63: 1246-54. PMID 7523587 DOI: 10.1046/J.1471-4159.1994.63041246.X  0.231
2021 Mestre TA, Macklin EA, Ascherio A, Ferreira JJ, Lang AE, Schwarzschild MA. Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 33942376 DOI: 10.1002/mds.28630  0.231
2009 Gao X, Schwarzschild MA, Wang H, Ascherio A. Obesity and restless legs syndrome in men and women. Neurology. 72: 1255-61. PMID 19349606 DOI: 10.1212/01.Wnl.0000345673.35676.1C  0.231
2014 Schwarzschild MA, Macklin EA, Ascherio A. Urate and neuroprotection trials. The Lancet. Neurology. 13: 758. PMID 25030508 DOI: 10.1016/S1474-4422(14)70138-3  0.229
2018 Nicholson K, Chan J, Macklin EA, Levine-Weinberg M, Breen C, Bakshi R, Grasso DL, Wills AM, Jahandideh S, Taylor AA, Beaulieu D, Ennist DL, Andronesi O, Ratai EM, Schwarzschild MA, et al. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology. 5: 1522-1533. PMID 30564619 DOI: 10.1002/Acn3.671  0.227
1991 Schwarzschild MA, Zigmond RE. Effects of peptides of the secretin-glucagon family and cyclic nucleotides on tyrosine hydroxylase activity in sympathetic nerve endings. Journal of Neurochemistry. 56: 400-6. PMID 1703218 DOI: 10.1111/J.1471-4159.1991.Tb08165.X  0.227
2023 Cook L, Verbrugge J, Schwantes-An TH, Schulze J, Beck JC, Naito A, Hall A, Chan AK, Casaceli CJ, Marder K, Nance M, Schwarzschild MA, Simuni T, Wills AM, Alcalay RN. Providing Genetic Testing and Genetic Counseling for Parkinson's Disease to the Community. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 100907. PMID 37302021 DOI: 10.1016/j.gim.2023.100907  0.223
2005 Frédérick R, Ooms F, Castagnoli N, Petzer JP, Feng JF, Schwarzschild MA, Van der Schyf CJ, Wouters J. (E)-8-(3-Chlorostyryl)-1,3,7-trimethylxanthine, a caffeine derivative acting both as antagonist of adenosine A2A receptors and as inhibitor of MAO-B. Acta Crystallographica. Section C, Crystal Structure Communications. 61: o531-2. PMID 16143772 DOI: 10.1107/S0108270105023140  0.22
1989 Schwarzschild MA, Vale W, Corigliano-Murphy AC, Pisano JJ, Ip NY, Zigmond RE. Activation of ganglionic tyrosine hydroxylase by peptides of the secretin-glucagon family: structure-function studies. Neuroscience. 31: 159-67. PMID 2570376 DOI: 10.1016/0306-4522(89)90037-7  0.22
1988 Rittenhouse AR, Schwarzschild MA, Zigmond RE. Both synaptic and antidromic stimulation of neurons in the rat superior cervical ganglion acutely increase tyrosine hydroxylase activity. Neuroscience. 25: 207-15. PMID 2899305 DOI: 10.1016/0306-4522(88)90019-X  0.218
1989 Schwarzschild MA, Zigmond RE. Secretin and vasoactive intestinal peptide activate tyrosine hydroxylase in sympathetic nerve endings. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 9: 160-6. PMID 2563276 DOI: 10.1523/Jneurosci.09-01-00160.1989  0.216
2004 Sakata M, Eguchi N, Qu WM, Huang ZL, Chen JF, Schwarzschild MA, Urade Y, Hayaishi O. Lack of rebound of non-rapid eye movement sleep after sleep deprivation in adenosine A2A receptor knockout mice Sleep and Biological Rhythms. 2: S56. DOI: 10.1111/J.1479-8425.2004.00115.X  0.216
2021 Flores-Torres MH, Hughes KC, Molsberry S, Gao X, Kang JH, Schwarzschild MA, Ascherio A. Cognitive function in men with non-motor features of Parkinson’s disease Bmj Neurology Open. 3: e000112. DOI: 10.1136/bmjno-2020-000112  0.212
2019 Shen Y, Li J, Schwarzschild M, Pavlova M, He S, Ascherio A, Wu S, Cui L, Gao X. Plasma urate concentrations and possible REM sleep behavior disorder. Annals of Clinical and Translational Neurology. PMID 31714690 DOI: 10.1002/Acn3.50929  0.211
2016 Jackson EK, Boison D, Schwarzschild MA, Kochanek PM. Purines: forgotten mediators in traumatic brain injury. Journal of Neurochemistry. 137: 142-53. PMID 26809224 DOI: 10.1111/Jnc.13551  0.211
1989 Zigmond RE, Schwarzschild MA, Rittenhouse AR. Acute regulation of tyrosine hydroxylase by nerve activity and by neurotransmitters via phosphorylation. Annual Review of Neuroscience. 12: 415-61. PMID 2564757 DOI: 10.1146/Annurev.Ne.12.030189.002215  0.209
2022 Liu G, Ni C, Zhan J, Li W, Luo J, Liao Z, Locascio JJ, Xian W, Chen L, Pei Z, Corvol JC, Maple-Grødem J, Campbell MC, Elbaz A, Lesage S, ... ... Schwarzschild MA, et al. Mitochondrial haplogroups and cognitive progression in Parkinson's disease. Brain : a Journal of Neurology. PMID 36343661 DOI: 10.1093/brain/awac327  0.206
2019 Bakshi R, Macklin EA, Schwarzschild MA. Reply to "Mitochondrial DNA deletions discriminate affected from unaffected LRRK2 mutation carriers". Annals of Neurology. 86: 326-327. PMID 31148194 DOI: 10.1002/Ana.25509  0.203
1993 Schwarzschild M. Nail in the Brain The New England Journal of Medicine. 328: 620-620. DOI: 10.1056/Nejm199303043280905  0.202
2022 Luo S, Zou H, Stebbins GT, Schwarzschild MA, Macklin EA, Chan J, Oakes D, Simuni T, Goetz CG. Dissecting the Domains of Parkinson's Disease: Insights from Longitudinal Item Response Theory Modeling. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 35841312 DOI: 10.1002/mds.29154  0.197
2009 Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Reply to Hernández Annals of Neurology. 65: 759. DOI: 10.1002/Ana.21730  0.175
2023 Fernandez HH, Weintraub D, Macklin E, Litvan I, Schwarzschild MA, Eberling J, Videnovic A, Kenney CJ. Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial. Parkinsonism & Related Disorders. 105511. PMID 37532622 DOI: 10.1016/j.parkreldis.2023.105511  0.144
2020 Bjornevik K, O'Reilly ÉJ, Cortese M, Furtado JD, Kolonel LN, Le Marchand L, Mccullough ML, Paganoni S, Schwarzschild MA, Shadyab AH, Manson JE, Ascherio A. Pre-diagnostic plasma lipid levels and the risk of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 1-11. PMID 32985910 DOI: 10.1080/21678421.2020.1822411  0.132
2023 Bjornevik K, Cortese M, Furtado JD, Paganoni S, Schwarzschild MA, Cudkowicz ME, Ascherio A. Association of Polyunsaturated Fatty Acids and Clinical Progression in Patients With ALS: Post Hoc Analysis of the EMPOWER Trial. Neurology. PMID 37344230 DOI: 10.1212/WNL.0000000000207485  0.121
2024 Ngo HKC, Le H, Ayer SJ, Crotty GF, Schwarzschild MA, Bakshi R. Short-term lipopolysaccharide treatment leads to astrocyte activation in LRRK2 G2019S knock-in mice without loss of dopaminergic neurons. Research Square. PMID 38562908 DOI: 10.21203/rs.3.rs-4076333/v1  0.12
2024 Keavney JL, Mathur S, Schroeder K, Merrell R, Castillo-Torres SA, Gao V, Crotty GF, Schwarzschild MA, Poma JM. Perspectives of People At-Risk on Parkinson's Prevention Research. Journal of Parkinson's Disease. PMID 38489198 DOI: 10.3233/JPD-230436  0.12
2024 Sandoval-Insausti H, Flores-Torres MH, Bjornevik K, Cortese M, Hung AY, Schwarzschild M, Yeh TS, Ascherio A. Flavonoid intake and risk of Parkinson's disease. Journal of Neurology, Neurosurgery, and Psychiatry. PMID 38267207 DOI: 10.1136/jnnp-2023-332672  0.12
1997 Hyman S, Schwarzschild M, Cole R. Glutamate, but not dopamine stimulates AP-1 mediated transcription in striatal neurons Biological Psychiatry. 42: 149S-150S. DOI: 10.1016/S0006-3223(97)87503-8  0.118
2020 Andronesi OC, Nicholson K, Jafari-Khouzani K, Bogner W, Wang J, Chan J, Macklin EA, Levine-Weinberg M, Breen C, Schwarzschild MA, Cudkowicz M, Rosen BR, Paganoni S, Ratai EM. Imaging Neurochemistry and Brain Structure Tracks Clinical Decline and Mechanisms of ALS in Patients. Frontiers in Neurology. 11: 590573. PMID 33343494 DOI: 10.3389/fneur.2020.590573  0.094
2023 Walk D, Nicholson K, Locatelli E, Chan J, Macklin EA, Ferment V, Manousakis G, Chase M, Connolly M, Dagostino D, Hall M, Ostrow J, Pothier L, Lieberman C, Gelevski D, ... ... Schwarzschild MA, et al. Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis. Muscle & Nerve. PMID 36840949 DOI: 10.1002/mus.27807  0.089
2023 Zhang X, Molsberry SA, Pavlova M, Schwarzschild MA, Ascherio A, Gao X. Probable Parasomnias and Mortality: A Prospective Study in US Men. Mayo Clinic Proceedings. 98: 1449-1457. PMID 37793724 DOI: 10.1016/j.mayocp.2023.06.018  0.075
2004 Chen J, Schwarzschild MA. Adenosine A2A receptors and neuroadaptation: Possible implications in sleep-wake physiology Sleep and Biological Rhythms. 2. DOI: 10.1111/J.1479-8425.2004.00093.X  0.074
2021 Bjornevik K, O'Reilly EJ, Molsberry S, Kolonel LN, Le Marchand L, Paganoni S, Schwarzschild MA, Benkert P, Kuhle J, Ascherio A. Prediagnostic Neurofilament Light Chain Levels in Amyotrophic Lateral Sclerosis. Neurology. PMID 34380747 DOI: 10.1212/WNL.0000000000012632  0.06
2018 Bhattacharyya S, Macklin EA, Schwarzschild MA. Cardiovascular Safety of Febuxostat. The New England Journal of Medicine. 379: 1582. PMID 30338966 DOI: 10.1056/NEJMc1809736#SA1  0.043
2023 West AB, Schwarzschild MA. LRRK2-Targeting Therapies March Through the Valley of Death. Movement Disorders : Official Journal of the Movement Disorder Society. 38: 361-365. PMID 36942368 DOI: 10.1002/mds.29343  0.037
2016 Jackson EK, Boison D, Schwarzschild MA, Kochanek PM. Purines: Forgotten mediators in traumatic brain injury Journal of Neurochemistry. DOI: 10.1111/jnc.13551  0.034
2020 Crotty GF, Lo RY, Schwarzschild MA. If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames? Movement Disorders : Official Journal of the Movement Disorder Society. 35: 1727-1730. PMID 33068466 DOI: 10.1002/mds.28240  0.024
2006 Fields RD, Robitaille R, Haydon PG, Raff MC, Mirsky R, Newman EA, Burnstock G, Schwarzschild MA, Schipke C, Illes P, Zalc B, Zimmermann H. General discussion III Novartis Foundation Symposium. 276: 233-237.  0.01
Hide low-probability matches.